Latest Basic, Translational and Clinical Advancements in HER2-Positive Breast Cancer

Dear colleagues,

Breast cancer is one of the most common malignancies worldwide. More than 400,000 cases of breast cancer were diagnosed in Europe in 2018, and about 98,000 deaths were recorded. Although the introduction of early diagnosis and novel therapeutic approaches to clinical practice has dramatically improved the clinical outcome of breast cancer patients, this malignant disease remains the second-leading cause of cancer-related death worldwide. 

Between 15% and 20% of breast cancers harbor HER2 overexpression and/or amplification, which is associated with an aggressive course of disease. While results overwhelmingly demonstrate the clinical benefit of HER2-targeted therapy, a considerable number of patients do not benefit. Thus, advancements in an improved understanding of HER2-positive breast cancer biology, immunology, metabolism, genomics, and epigenetics, as well as the selection of more suited tailored treatments and predictive criteria of response to therapies, are still mandatory goals to be achieved. Indeed, HER2-driven cancer recurrence continues to be a real and significant clinical concern. This Special Issue will bring together expert researchers and physicians focusing on the latest key findings in the field of HER2-driven basic and translational research. It will also cover innovations in detection tools and treatment options of HER2-positive breast cancer.

Dr. Serenella Pupa
Dr. Elda Tagliabue
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.